Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
The type species of BETARETROVIRUS commonly latent in mice. It causes mammary adenocarcinoma in a genetically susceptible strain of mice when the appropriate hormonal influences operate.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
A malignant epithelial tumor with a glandular organization.

Control of metastasis by Asn-linked, beta1-6 branched oligosaccharides in mouse mammary cancer cells. (1/1158)

Studies in cell lines and malignant human tissues have shown that increased cell-surface Asn-linked beta1-6(GlcNAcbeta1-6Man) branching is associated with increased tumorigenic and metastatic properties. In this study, three mouse mammary cancer cell lines were transfected with an expression vector containing the mouse cDNA for N-acetylglucosaminyltransferase V (GlcNAcT-V EC 2.4.1.155), the glycosyltransferase responsible for initiating beta1-6 branching on Asn-linked carbohydrates. The cell lines were screened for increased cytotoxicity to L-PHA, a lectin specific for beta1-6 branching structures. Cell lines exhibiting increased L-PHA cytotoxicity expressed increased levels of beta1-6 branching structures. Northern blots detected the presence of GlcNAcT-V transcribed from the expression vector in the L-PHA sensitive cell lines. After injection into the tail veins of mice, transfected cell lines with increased beta1-6 branching on the cell surface formed elevated levels of lung tumors relative to control transfected cell lines (P < 0.002). Western blots of membrane proteins from GlcNAcT-V transfected and control cells probed with the lectins DSA and WGA did not show an increase in polyN-acetyllactosamine and sialic acid content in the transfected cell lines. These results demonstrate that a specific increase in beta1-6 branching due to an elevation in GlcNAcT-V expression increases metastatic potential.  (+info)

Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. (2/1158)

In order to evaluate the involvement of c-yes and c-erbB-2 oncogene products, and p53 tumor suppressor protein in canine mammary neoplastic lesions, sections of archived paraffin-embedded samples of 79 mammary tumors were analyzed immunohistochemically using antibodies against human c-yes p62 and c-erbB-2 products and p53. These 79 tumors were divided into 2 groups: 32 benign (2 adenosis, 7 simple adenomas, 14 complex adenomas, and 9 benign mixed mammary tumors) and 47 malignant tumors (26 simple adenocarcinomas, 7 complex adenocarcinomas, 5 solid carcinomas, 2 sclerosing carcinomas, 6 malignant mixed mammary tumors, and 1 malignant myoepithelioma). As a result of immunostaining, 40.6% (13/32) of the benign tumors and 21.3% (10/47) of the malignant tumors expressed the c-Yes oncogene product, ErbB-2 expression was detected in 50% (16/32) of the benign tumors and in 19.1% (9/47) of the malignant tumors. P53 expression was detected in 16% (4/25) of the benign tumors and in 30.6% (11/36) of the malignant tumors. Co-expression of c-Yes and ErbB-2, ErbB-2 and p53, and all 3 products was detected in 6, 1 and 7 tumors, respectively.  (+info)

T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. (3/1158)

It is widely accepted that cellular immune responses are induced by CD4(+) T helper 1 (Th1) cells secreting interleukin (IL)-2 and interferon (IFN)-gamma. Tumor immunity is often mediated by cytotoxic T lymphocytes (CTLs) whose activation is supported by Th1 cytokines. Since IL-4 directs Th2 development and has been shown to inhibit Th1-dominated responses, we assumed that IL-4-deficient (IL-4(-/-)) mice would develop vigorous CTL-mediated tumor immunity compared with IL-4-competent (IL-4(+/+)) mice. Surprisingly, IL-4(-/-) mice were severely impaired to develop tumor immunity to both a mammary adenocarcinoma line and a colon carcinoma line. The lack of tumor immunity in IL-4(-/-) mice was associated with reduced IFN-gamma production, diminished levels of tumor-reactive serum IgG2a, and undetectable CTL activity, indicating a defective Th1 response in the absence of endogenous IL-4. Anti-IL-4 monoclonal antibody blocked tumor immunity in IL-4(+/+) mice when administered at the time of immunization but not at the time of challenge. Additionally, tumor immunity could be induced in IL-4(-/-) mice, if IL-4 was provided by gene-modified cells together with immunizing tumor cells. These results demonstrate that tumor immunity requires IL-4 in the priming phase for the generation of effector cells rather than for their maintenance and exclude secondary, developmental defects in the "knockout" strain. Together, our results demonstrate a novel and previously unanticipated role of IL-4 for the generation of Th1-associated, CTL-mediated tumor immunity.  (+info)

Amplification of the c-yes oncogene in canine mammary tumors. (4/1158)

Genomic DNAs of 14 mammary tumors were analyzed by Southern blot hybridization using a human c-yes-1 oncogene probe. The amplification was successful in half of the cases (7 adenocarcinomas). The degree of amplification was approximately 4-fold, and a high proportion was seen in malignant tumors. In addition, DNA polymorphism was detected in two adenocarcinomas.  (+info)

Walker 256/S carcinosarcoma causes osteoporosis-like changes through ectopical secretion of luteinizing hormone-releasing hormone. (5/1158)

We have shown that Walker 256/S mammary carcinoma caused osteoporosis-like changes in young female rats, accompanied by low serum estradiol and hypercalciuria without changes in the serum levels of calcium, phosphorus, and parathyroid hormone-related peptide. In this study, we investigated the cause of bone loss after Walker 256/S inoculation into female 6-week-old Wistar Imamichi rats, focusing on the sex hormone balance in the host animal. Walker 256/S-bearing rats showed characteristic osteoporosis, with a significant increase in spleen weight and a significant decrease in uterine weight by 14 days after s.c. tumor inoculation. In the in vitro bone marrow culture, mineralized nodule formation ability decreased according to the time after tumor inoculation, and tartrate-resistant acid phosphatase-positive multinucleated cell formation increased at 7 days after tumor inoculation, but it began to decrease at 14 days after tumor inoculation. This indicates that after inoculation with Walker 256/S tumor, the progenitors of osteoblasts and ostroclasts lost their balance in the bone turnover, resulting in bone resorption. On the other hand, Walker 256/S carcinoma expressed luteinizing hormone-releasing hormone (LH-RH) mRNA, and in Walker 256/S-bearing rats, the serum LH-RH level increased significantly from 3 days after tumor inoculation, whereas in the healthy control rats, this level was very low. Consequently, the serum levels of follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone were significantly lower in the tumor-bearing rats than in the healthy control rats. Because the LH-RH gene is located in the long prolactin release-inhibiting factor (PIF) gene and mRNA amplified by reverse transcription-PCR in this study contained whole LH-RH and a part of PIF, the Walker 256/S tumor is thought to express PIF. Indeed, the serum prolactin level decreased in tumor-bearing rats. The serum level of growth hormone, one of the other pituitary hormones, was not changed. Moreover, the level of an osteolytic cytokine, tumor necrosis factor alpha, increased in the serum of Walker 256/S-bearing rats, although this may be a result of the immune response of the host animal to tumor growth as well as an enlarged spleen. In conclusion, the Walker 256/S tumor lowers estrogen secretion through ectopical oversecretion of LH-RH, and then osteolytic cytokines, such as tumor necrosis factor alpha, increase in tumor-bearing rats, escape the control of estrogen, and activate osteoclasts, resulting in bone loss in a short period.  (+info)

Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. (6/1158)

Poly(L-glutamic acid)-paclitaxel (PG-TXL) is a new water-soluble paclitaxel derivative that has shown remarkable antitumor activity against both ovarian and breast tumors. The purpose of this study was to test whether the antitumor efficacy of PG-TXL depends on tumor type, as is the case for paclitaxel, and to test whether paclitaxel-resistant tumors could be responsive to PG-TXL. We evaluated the therapeutic activity of PG-TXL against four syngeneic murine tumors (MCa-4, MCa-35, HCa-1, and FSa-II) inoculated i.m. into C3Hf/Kam mice, a human SKOV3ip1 ovarian tumor injected i.p. into nude mice, and a human MDA-MB-435Lung2 breast tumor grown in the mammary fat pad of nude mice. Two paclitaxel-responsive murine tumors, MCa-4 and MCa-35, showed significant growth delay with PG-TXL given as a single i.v. injection at its maximum tolerated dose of 160 mg of equivalent paclitaxel/kg or even at a lower dose of 120 mg of equivalent paclitaxel/kg. The other two murine tumors, HCa-1 and FSa-II, did not respond particularly well to either of the two agents, although significant growth delay was observed for both tumors with PG-TXL. In mice with SKOV3ip1 tumors, the median survival times for mice treated with PG alone and PG-TXL at doses of 60 or 120 mg of equivalent paclitaxel/kg were 43, 61, and 75 days, respectively; no survival difference was found between paclitaxel-treated and Cremophor vehicle-treated mice. In mice with MDA-MB-435Lung2 tumor, PG-TXL at a dose of 120 mg of equivalent paclitaxel/kg produced regression of the tumor in 50% of the animals, and in the remaining mice, micrometastases in the lung were found only in 25% of the animals. In comparison, treatment with paclitaxel at 60 mg/kg did not result in tumor regression, and the rate of lung metastases was 42%. These results clearly demonstrate that PG-TXL has significant therapeutic activity against breast and ovarian tumors tested in this study. Future studies to elucidate the mechanism of action of PG-TXL and to assess its clinical applications are warranted.  (+info)

A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. (7/1158)

Estrogens have important functions in mammary gland development and carcinogenesis. To better define these roles, we have used two previously characterized lines of genetically altered mice: estrogen receptor-alpha (ER alpha) knockout (ERKO) mice, which lack the gene encoding ER alpha, and mouse mammary virus tumor (MMTV)-Wnt-1 transgenic mice (Wnt-1 TG), which develop mammary hyperplasia and neoplasia due to ectopic production of the Wnt-1 secretory glycoprotein. We have crossed these lines to ascertain the effects of ER alpha deficiency on mammary gland development and carcinogenesis in mice expressing the Wnt-1 transgene. Introduction of the Wnt-1 transgene into the ERKO background stimulates proliferation of alveolar-like epithelium, indicating that Wnt-1 protein can promote mitogenesis in the absence of an ER alpha-mediated response. The hyperplastic glandular tissue remains confined to the nipple region, implying that the requirement for ER alpha in ductal expansion is not overcome by ectopic Wnt-1. Tumors were detected in virgin ERKO females expressing the Wnt-1 transgene at an average age (48 weeks) that is twice that seen in virgin Wnt-1 TG mice (24 weeks) competent to produce ER alpha. Prepubertal ovariectomy of Wnt-1 TG mice also extended tumor latency to 42 weeks. However, pregnancy did not appear to accelerate the appearance of tumors in Wnt-1 TG mice, and tumor growth rates were not measurably affected by late ovariectomy. Small hyperplastic mammary glands were observed in Wnt-1 TG males, regardless of ER alpha gene status; the glands were similar in appearance to those found in ERKO/Wnt-1 TG females. Mammary tumors also occurred in Wnt-1 TG males; latency tended to be longer in the heterozygous ER alpha and ERKO males (86 to 100 weeks) than in wild-type ER alpha mice (ca. 75 weeks). We conclude that ectopic expression of the Wnt-1 proto-oncogene can induce mammary hyperplasia and tumorigenesis in the absence of ER alpha in female and male mice. The delayed time of tumor appearance may depend on the number of cells at risk of secondary events in the hyperplastic glands, on the carcinogenesis-promoting effects of ER alpha signaling, or on both.  (+info)

Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. (8/1158)

The mechanisms of action of the anticancer agent perillyl alcohol (POH), presently in Phase II clinical trials, were investigated in advanced rat mammary carcinomas. Gross and ultrastructural morphology of POH-mediated tumor regression indicated that apoptosis accounted for the marked reduction in the epithelial compartment. Characterization of cell growth and death indices revealed that apoptosis was induced within 48 h of chemotherapy, before the induction of cytostasis. RNA expression studies, based on a multiplexed-nuclease protection assay, demonstrated that cell cycle- and apoptosis-related genes were differentially expressed within 48 h of POH treatment; p21(Cip1/WAF1), bax, bad, and annexin I were induced; cyclin E and cyclin-dependent kinase 2 were repressed; and bcl-2 and p53 were unchanged. Next, a potential role for transforming growth factor beta (TGF-beta) signaling in POH-mediated carcinoma regression was explored. RNA expression studies, again based on a multiplexed-nuclease protection assay, showed that TGF-beta-related genes were induced and temporally regulated during POH treatment: (a) c-jun and c-fos were transiently induced within 12 h of chemotherapy; (b) TGF-beta1 was induced within 24 h of chemotherapy; (c) the mannose 6-phosphate/insulin-like growth factor II receptor and the TGF-beta type I and II receptors were induced within 48 h of chemotherapy; and (d) smad3 was induced during active carcinoma regression. In situ protein expression studies, based on fluorescence-immunohistochemistry in concert with confocal microscopy, confirmed up-regulation and demonstrated colocalization of TGF-beta1, the mannose 6-phosphate/insulin-like growth factor II receptor, the TGF-beta type I and II receptors, and Smad2/Smad3 in epithelial cells. Nuclear localization of Smad2/Smad3 indicated that the TGF-beta signaling pathway was activated in regressing carcinomas. Subpopulations of Smad2/Smad3-positive and apoptotic nuclei colocalized, indicating a role for Smads in apoptosis. Thus, Smads may serve as a potential biomarker for anticancer activity. Importantly, none of the POH-mediated anticancer activities were observed in normal mammary gland.  (+info)

Mammary neoplasms in animals refer to abnormal growths or tumors that occur in the mammary glands. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign tumors are slow growing and rarely spread to other parts of the body, while malignant tumors are aggressive, can invade surrounding tissues, and may metastasize to distant organs.

Mammary neoplasms are more common in female animals, particularly those that have not been spayed. The risk factors for developing mammary neoplasms include age, reproductive status, hormonal influences, and genetic predisposition. Certain breeds of dogs, such as poodles, cocker spaniels, and dachshunds, are more prone to developing mammary tumors.

Clinical signs of mammary neoplasms may include the presence of a firm, discrete mass in the mammary gland, changes in the overlying skin such as ulceration or discoloration, and evidence of pain or discomfort in the affected area. Diagnosis is typically made through a combination of physical examination, imaging studies (such as mammography or ultrasound), and biopsy with histopathological evaluation.

Treatment options for mammary neoplasms depend on the type, size, location, and stage of the tumor, as well as the animal's overall health status. Surgical removal is often the primary treatment modality, and may be curative for benign tumors or early-stage malignant tumors. Radiation therapy and chemotherapy may also be used in cases where the tumor has spread to other parts of the body. Regular veterinary check-ups and monitoring are essential to ensure early detection and treatment of any recurrence or new mammary neoplasms.

There is no medical definition for "dog diseases" as it is too broad a term. However, dogs can suffer from various health conditions and illnesses that are specific to their species or similar to those found in humans. Some common categories of dog diseases include:

1. Infectious Diseases: These are caused by viruses, bacteria, fungi, or parasites. Examples include distemper, parvovirus, kennel cough, Lyme disease, and heartworms.
2. Hereditary/Genetic Disorders: Some dogs may inherit certain genetic disorders from their parents. Examples include hip dysplasia, elbow dysplasia, progressive retinal atrophy (PRA), and degenerative myelopathy.
3. Age-Related Diseases: As dogs age, they become more susceptible to various health issues. Common age-related diseases in dogs include arthritis, dental disease, cancer, and cognitive dysfunction syndrome (CDS).
4. Nutritional Disorders: Malnutrition or improper feeding can lead to various health problems in dogs. Examples include obesity, malnutrition, and vitamin deficiencies.
5. Environmental Diseases: These are caused by exposure to environmental factors such as toxins, allergens, or extreme temperatures. Examples include heatstroke, frostbite, and toxicities from ingesting harmful substances.
6. Neurological Disorders: Dogs can suffer from various neurological conditions that affect their nervous system. Examples include epilepsy, intervertebral disc disease (IVDD), and vestibular disease.
7. Behavioral Disorders: Some dogs may develop behavioral issues due to various factors such as anxiety, fear, or aggression. Examples include separation anxiety, noise phobias, and resource guarding.

It's important to note that regular veterinary care, proper nutrition, exercise, and preventative measures can help reduce the risk of many dog diseases.

'Mammary neoplasms, experimental' is not a recognized medical term. However, I can provide definitions for the individual terms:

1. Mammary: Pertaining to the breast or mammary glands in females, which are responsible for milk production.
2. Neoplasms: Abnormal growths of tissue, also known as tumors or masses, that can be benign (non-cancerous) or malignant (cancerous).
3. Experimental: Relating to a scientific experiment or study, typically conducted in a controlled setting to test hypotheses and gather data.

In the context of medical research, 'experimental mammary neoplasms' may refer to artificially induced breast tumors in laboratory animals (such as rats or mice) for the purpose of studying the development, progression, treatment, and prevention of breast cancer. These studies can help researchers better understand the biology of breast cancer and develop new therapies and strategies for its diagnosis and management.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Carcinosarcoma is a rare and aggressive type of cancer that occurs when malignant epithelial cells (carcinoma) coexist with malignant mesenchymal cells (sarcoma) in the same tumor. This mixed malignancy can arise in various organs, but it is most commonly found in the female reproductive tract, particularly in the uterus and ovaries.

In a carcinosarcoma, the epithelial component typically forms glands or nests, while the mesenchymal component can differentiate into various tissue types such as bone, cartilage, muscle, or fat. The presence of both malignant components in the same tumor makes carcinosarcomas particularly aggressive and challenging to treat.

Carcinosarcomas are also known by other names, including sarcomatoid carcinoma, spindle cell carcinoma, or pseudosarcoma. The prognosis for patients with carcinosarcoma is generally poor due to its high propensity for local recurrence and distant metastasis. Treatment usually involves a combination of surgery, radiation therapy, and chemotherapy.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

Medical Definition:

Mammary tumor virus, mouse (MMTV) is a type of retrovirus that specifically infects mice and is associated with the development of mammary tumors or breast cancer in these animals. The virus is primarily transmitted through mother's milk, leading to a high incidence of mammary tumors in female offspring.

MMTV contains an oncogene, which can integrate into the host's genome and induce uncontrolled cell growth and division, ultimately resulting in the formation of tumors. While MMTV is not known to infect humans, it has been a valuable model for studying retroviral pathogenesis and cancer biology.

Disseminated Intravascular Coagulation (DIC) is a complex medical condition characterized by the abnormal activation of the coagulation cascade, leading to the formation of blood clots in small blood vessels throughout the body. This process can result in the consumption of clotting factors and platelets, which can then lead to bleeding complications. DIC can be caused by a variety of underlying conditions, including sepsis, trauma, cancer, and obstetric emergencies.

The term "disseminated" refers to the widespread nature of the clotting activation, while "intravascular" indicates that the clotting is occurring within the blood vessels. The condition can manifest as both bleeding and clotting complications, which can make it challenging to diagnose and manage.

The diagnosis of DIC typically involves laboratory tests that evaluate coagulation factors, platelet count, fibrin degradation products, and other markers of coagulation activation. Treatment is focused on addressing the underlying cause of the condition while also managing any bleeding or clotting complications that may arise.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

A mammary tumor is a neoplasm originating in the mammary gland. It is a common finding in older female dogs and cats that are ... There are many differences between mammary tumors in animals and breast cancer in humans, including tumor type, malignancy, and ... Benjamin S, Lee A, Saunders W (1999). "Classification and behavior of canine mammary epithelial neoplasms based on life-span ... Spayed rats have a decreased risk of developing mammary tumors. Most mammary tumors in mice are adenocarcinomas. They can be ...
Laboratory mouse Animal testing on rodents Morris water maze Rat Genome Database Vandenbergh, J. G. (1 January 2000). "Use of ... The most common are adenomas of the pituitary and adenomas/adenocarcinomas of the adrenal cortex in both sexes, mammary gland ... Mac Kenzie, William; Garner, F. (1973). "Comparison of Neoplasms in Six Sources of Rats". JNCI: Journal of the National Cancer ... Institute for Laboratory Animal Research (ILAR). 32 (3): 4-8. doi:10.1093/ilar.32.3.4. Suckow, Mark A.; Weisbroth, Steven H.; ...
In animals, the bioavailability of hydroxyprogesterone caproate with intramuscular injection is nearly 100%, but its oral ... Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds ... Crowley LG, Macdonald I (April 1965). "Delalutin and estrogens for the treatment of advanced mammary carcinoma in the ... Crowley LG, Macdonald I (1962). "Clinical trial of delautin in the treatment of advanced mammary carcinoma in postmenopausal ...
Dunn, Thelma B. "Morphology of Mammary Tumors in Mice" (1958). "Studies of the Mammary-Tumor Agent of Strain RIII Mice". JNCI: ... "Histology of Some Neoplasms and Non-Neo-plastic Lesions Found in Wild Mice Maintained Under Laboratory Conditions". JNCI: ... She developed methods of inducing malignant tumors in the stomachs and intestines of experimental animals and studied the ... "Studies of the Mammary-Tumor Agent of Strain RIII Mice" (1961), "Further Studies of the Mammary Tumor Agent of Strain RIII Mice ...
The majority of deaths were caused by neoplasms, mainly mammary tumours. The Siamese also has a higher rate of morbidity. They ... April 2006). "Albinism in the domestic cat (Felis catus) is associated with a tyrosinase (TYR) mutation". Animal Genetics. 37 ( ... London: Hodder & Stoughton Wilson, Staci Layne (2007). Animal Movies Guide. Running Free Press. p. 16. ISBN 9780967518534. New ... "Congenital Deafness and Its Recognition". Veterinary Clinics of North America: Small Animal Practice. Retrieved 15 January 2015 ...
During this period he first had the idea to use mice to find a cure for mammary cancer in animals. Ansfield received his M.D. ... Ansfield, Fred J (1973). Chemotherapy of Malignant Neoplasms (Second ed.). Springfield, Illinois: Charles C Thomas. ISBN 0-398- ... 1958 Chemotherapy of Malignant Neoplasms, 1973 Chemotherapy of Disseminated Solid Tumors, 1966 Mehta, Minesh P.; Paliwal, ...
Annual Review of Animal Biosciences. 4 (1): 199-222. doi:10.1146/annurev-animal-022114-110911. PMC 6314649. PMID 26566160. Pang ... Other significant risk factors were a high intake of red meat, especially beef and pork (...) We found mammary tumor risk to be ... Cancer alters the DNA of cells and the mutated genetic material is passed on to daughter cells, resulting in neoplasms. The ... Veterinary oncology is the medical study of cancer in animals, and can be diagnosed and treated by specialized veterinarians ...
Animal. 41 (1-2): 19-28. doi:10.1290/0502010.1. PMID 15926856. S2CID 1995302. Przyborski SA (2001). "Isolation of human ... Smalley MJ, Clarke RB (January 2005). "The mammary gland "side population": a putative stem/progenitor cell marker?". Journal ... Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... Clarke RB (December 2005). "Isolation and characterization of human mammary stem cells". Cell Proliferation. 38 (6): 375-86. ...
FDA routinely requires long-term animal studies before any drug can be marketed for human use. Following animal studies with ... In the early 1970s, MGA was found to be associated with mammary tumors in beagle dogs, and along with several other ... Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Der Urologe (in German). 10 (3): 117- ... Small Animal Practice. 33 (2): 365-404, vii. doi:10.1016/S0195-5616(02)00130-4. PMID 12701517. Canetta R, Florentine S, Hunter ...
Furthermore, it leads to a phase delay of circadian rhythm in nocturnal and diurnal animal models. N-benzothiazolyl-2-phenyl ... Besides those, reduced CK1Ī“ activity owing to the site N172D mutation of CK1Ī“ decelerated mammary carcinoma progression, and ... hematopoietic malignancies and lymphoid neoplasms. Also decreased CK1Ī“ mRNA expression levels have been observed in some cancer ... Ever since, CK1Ī“ was investigated and described in various animals, plants, as well as parasites (Caenorhabditis elegans, 1998 ...
"The role of animal behaviour in the study of endocrine-disrupting chemicals". Animal Behaviour. 68 (4): 665-676. doi:10.1016/j. ... Neoplasms occurring in epithelial tissue such as the liver, gastrointestinal tract, and the pancreas have been linked to ... In females, this includes mammary glands, fallopian tubes, uterus, cervix, and vagina. In males, this includes the prostate, ... Alternatives to Laboratory Animals 31: 277-281. Boelsterli, Urs. Mechanistic Toxicology: The molecular basis of how chemicals ...
... control animal - control group - controlled clinical trial - controlled study - conventional therapy - conventional treatment ... mammary - mammogram - mammography - Mammotome - mantle field - marimastat - mast cell - mastectomy - mastocytoma - matrix ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... animal model - annamycin - anorexia - ansamycin - antagonist - anterior mediastinotomy - anterior mediastinum - anthracenedione ...
In 1968, Jackson and Langham published the first NMR signals from a living animal, an anesthetized rat. In the 1970s, it was ... Irwin Weisman also found in 1972 that neoplasms display different relaxation times than corresponding normal tissue. Zenuemon ... "Distinction between the preneoplastic and neoplastic state of murine mammary glands". Proceedings of the National Academy of ... In research laboratories, human studies have been performed at 9.4 T (2006) and up to 10.5 T (2019). Non-human animal studies ...
Dissociated mammary cells from MMTV-PyMT: IRES: Luc; MTB (Internal ribosome entry site: Luciferin) animals (which were not ... It also confirms the genetic heterogeneity between the primary neoplasm of breast cancer patients and their respective ... In the non-fused mouse, the mammary gland would revert to a near virgin, but with this addition the mammary gland maintained ... Whey acidic protein (WAP), is another common promoter used to generate mouse mammary cancer models. For a list of other mammary ...
"A glimpse into Canada's highest containment laboratory for animal health: The National Centre for Foreign Animal Diseases". ... Male reproductive system - Mammary gland - Mandible - The mandible, lower jaw or jawbone is the largest, strongest and lowest ... Papillary - In oncology, papillary refers to neoplasms with projections ("papillae", from Latin, 'nipple') that have ... Plant life and animal life rely on many organs that co-exist in organ systems. Oral and maxillofacial surgery - is a surgical ...
As a mammary gland, the breast comprises lobules (milk glands at each lobe-tip) and the lactiferous ducts (milk passages), ... Obesity or being overweight in humans and most animals does not depend on body weight but on the amount of body fat - to be ... liposuction mammoplasty also is contraindicated for any woman whose mammograms indicate the presence of unevaluated neoplasms; ... The 2nd, 3rd, 4th, 5th, and 6th ribs of the thoracic cage are the structural supports for the mammary glands. Chest muscles. ...
Acral lentiginous melanoma Amelanotic melanoma Animal-type melanoma Desmoplastic melanoma (neurotropic melanoma, spindled ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... Turner syndrome Ulnar-mammary syndrome Van Der Woude syndrome Von Hippel-Lindau syndrome Watson syndrome Werner syndrome (adult ... an overview with emphasis on the myeloid neoplasms". Chem. Biol. Interact. 184 (1-2): 16-20. doi:10.1016/j.cbi.2009.10.009. ...
Clark JH, Hardin JW, McCormack SA (1979). "Mechanism of action of estrogen agonists and antagonists". Journal of Animal Science ... Estrogens and Androgens in Mammary Cancer". JAMA: The Journal of the American Medical Association. 140 (15): 1214. doi:10.1001/ ... "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli, David G. Johns (eds.). ... "Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of nine hundred forty-four ...
Rusyn I, Lemon SM (April 2014). "Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies?". ... In 1936 John Joseph Bittner identified the mouse mammary tumor virus, an "extrachromosomal factor" (i.e. virus) that could be ... Stewart SE, Eddy BE, Borgese N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ... A minority of persons (or animals) will go on to develop cancers after infection. This has complicated efforts to determine ...
TGF-Ī², which acts in the epithelial cells of the mammary gland as a potent tumor suppressor at the early stages of cancer, can ... Studies in animal models have demonstrated that metastases more often form after intravenous injection of tumor clusters rather ... The factors limiting the growth of malignant neoplasms include the basement membrane and various components of the surrounding ... The results of numerous experimental and clinical studies of malignant neoplasms have indicated that invasive growth and ...
Transgenic mice expressing either p75, p110 or p200 CUX1 in mammary epithelial cells develop mammary tumours with a low ... CUX1 is an animal gene. The name stands for Cut like homeobox 1. The term "cut" derives from the "cut wing" phenotype observed ... "Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression". Blood 2011, 118:167-76. ... Transgenic mice expressing this transcript in mammary epithelial cells were shown to develop mammary tumours with metastasis to ...
Animals, typically rodents, are often used in cancer research and studies of natural cancers in larger animals may benefit ... They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... The German professor Wilhelm Fabry believed that breast cancer was caused by a milk clot in a mammary duct. The Dutch professor ... Across wild animals, there is still limited data on cancer. Nonetheless, a study published in 2022, explored cancer risk in ( ...
The Notch signaling pathway is a highly conserved cell signaling system present in most animals. Mammals possess four different ... "Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells". Breast Cancer Research. 6 (6): R605 ... is broken by chromosomal translocations in T lymphoblastic neoplasms". Cell. 66 (4): 649-61. doi:10.1016/0092-8674(91)90111-B. ... Hedgehog signaling and Scl T cell lineage commitment from common lymphoid precursor regulation of cell-fate decision in mammary ...
There are also reports of the use of thymidine kinase as a tumor marker in domestic animals, in horse, in dogs in cats and in ... Lipkin M, Deschner E, Troncale F (1970). "Cell differentiation and the development of colonic neoplasms". CA: A Cancer Journal ... and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker". BMC Veterinary Research. 10: 228. doi: ... "Increased activities of thymidine kinase isozymes in human mammary tumours". The British Journal of Surgery. 73 (4): 272-3. doi ...
... as well as eliminating infected animals and screening incoming animals, should clear the problem very quickly. Imported animals ... Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal ... immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis". Anticancer ... and has oncolytic properties demonstrated in animal models and in naturally-occurring cancers in animals. SeV's ability to fuse ...
Animals were assigned to one of five groups: sham exercise or 35% ā€¦ ... Mammary Neoplasms, Experimental / chemically induced * Mammary Neoplasms, Experimental / prevention & control* * ... Animals were assigned to one of five groups: sham exercise or 35% or 70% maximal treadmill running intensity for 20 or 40 min/ ... Mammary cancer incidence was reduced by as much as 37% and cancer multiplicity by , 60% at the highest exercise intensity. ...
A mammary tumor is a neoplasm originating in the mammary gland. It is a common finding in older female dogs and cats that are ... There are many differences between mammary tumors in animals and breast cancer in humans, including tumor type, malignancy, and ... Benjamin S, Lee A, Saunders W (1999). "Classification and behavior of canine mammary epithelial neoplasms based on life-span ... Spayed rats have a decreased risk of developing mammary tumors. Most mammary tumors in mice are adenocarcinomas. They can be ...
... but are rarely observed in farm animals. Infrequent cases of mammary neoplasms have been reported in cattle (POVEY & OSBORNE, ... Mammary hyperplasia is diagnosed commonly in company animals, but rarely in herbivores (HONG, 1994HONG, C.B. Mammary nodular ... In Vivo, v.4, p.33-40, 1990.; MISDORP, 2002MISDORP, W. Tumors of the mammary gland. In: MEUTEN, D.J. Tumors in domestic animals ... In: MEUTEN, D.J. Tumors in domestic animals. Ames: Iowa State University, 2002. p.575-606.). Recently, three cases of mammary ...
MAMMARY NEOPL ANIMAL. Entry Term(s). Animal Mammary Carcinoma Mammary Carcinoma, Animal Mammary Neoplasms Neoplasms, Mammary ... Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).. Terms. Mammary Neoplasms, Animal Preferred Term ... Hematologic Neoplasms [C04.588.448] * Mammary Neoplasms, Animal [C04.588.531] * Mammary Neoplasms, Experimental [C04.588. ... Mammary Carcinoma, Animal Narrower Concept UI. M0445538. Terms. Mammary Carcinoma, Animal Preferred Term Term UI T532356. Date ...
Mammary Glands, Animal / growth & development * Mammary Neoplasms, Animal / etiology * Mammary Neoplasms, Animal / genetics* ... 1,2). We have previously reported a mouse model in which Brca1 exon 11 is eliminated in mammary epithelial cells through Cre- ... However, most female Brca1Delta11/Delta11 Trp53+/- mice develop mammary tumors with loss of the remaining Trp53 allele within 6 ... Unexpectedly, elimination of one Trp53 allele completely rescues this embryonic lethality and restores normal mammary gland ...
Long-term follow-up was available in 5 goats with mammary neoplasia that underwent bilateral mastectomy. No evidence of mass ... RESULTS 46 goats with 58 neoplasms were identified. The prevalence of neoplasia within the study population was 3.2%. The most ... CLINICAL RELEVANCE Goats are increasingly treated as companion rather than strictly production animals, making it important for ... commonly diagnosed neoplasms were squamous cell carcinoma, thymoma, and mammary carcinoma. The Saanen breed was the most common ...
Other neoplasms present in pyrrolizidine alkaloid exposed animals included (in order of prevalence): lymphoma (5), ... mammary carcinoma (3), bronchoalveolar tumors (2), osteosarcoma (2), sarcoma not otherwise specified (2), leydig cell tumor (1 ... Other neoplasms present in pyrrolizidine alkaloid exposed animals included (in order of prevalence): lymphoma (5), ... Current small animal models require large numbers of animals over a long period of time (years), and are insensitive for ...
... was the lack of effects of UWB-pulse exposure on promotion of mammary tumors in a well-established animal model of mammary ... Histopathological evaluations revealed no significant differences between the two groups in numbers of neoplasms in all tissues ... long-term exposure of mammary tumor-prone mice to 435 MHz or 2450 MHz RF radiation did not affect the incidence of mammary ... Repeated Exposure of C3H/HeJ Mice to Ultra-wideband Electromagnetic Pulses: Lack of Effects on Mammary Tumors ...
Mammary neoplasms gland mainly occurred in females (94%) and in crossbred animals (38.3%). Dogs older than 10 years of age were ... Mammary neoplasms gland mainly occurred in females (94%) and in crossbred animals (38.3%). Dogs older than 10 years of age were ... Mammary neoplasms gland mainly occurred in females (94%) and in crossbred animals (38.3%). Dogs older than 10 years of age were ... Mammary neoplasms gland mainly occurred in females (94%) and in crossbred animals (38.3%). Dogs older than 10 years of age were ...
Tumors of the mammary gland. In: Tumors in domestic animals. 5th edn. Ames: John Wiley & Sons, Inc, pp.723-765. ... Discussion: anaplastic carcinoma of the mammary gland has an epithelial origin and is considered the most malignant neoplasm ... Paraneoplastic hematological, biochemical, and hemostatic abnormalities in female dogs with mammary neoplasms. Pesquisa ... Hemorrhagic Stroke in a Dog with Anaplastic Carcinoma of the Mammary Gland Authors. * Bianca Santana de Cecco Setor de ...
Tumors of the mammary gland. In: WITHROW, S.J. et al. Withrow & MacEwen`s small animal clinical oncology. 5.ed. St. Louis: ... In view of the absence of reports regarding adiponectin levels in dogs and the occurrence of malignant neoplasms, the present ... Despite the small number of animals in each group, it is important to note that the group of bitches diagnosed with mammary ... Mammary carcinoma- bearing dogs. Breed and age. Adiponectin (Ī¼g/mL). Weight (kg). BCS. Clinically normal dogs. Breed and age. ...
These animal studies have reinforced the findings of the Du Pont mortality study of workers exposed to AN which, though ... Other findings included papillomata in the stomach, hemangioma of the kidney, fibroadenomas of the mammary gland, benign tumors ... squamous cell neoplasms of the Zymbal gland, adenocarcinoma of the small intestine and large intestine, along with numerous ... Two year feeding and inhalation studies with animals indicated the chemical to be carcinogenic, producing tumors of the central ...
Mammary Neoplasms, Animal. Receptor, ErbB-3. Apoptosis. Mammary Neoplasms, Experimental. Cell Line, Tumor. Cell Proliferation. ... Triple Negative Breast Neoplasms. Hormone Replacement Therapy. Thyroid Hormones. Neoplasms, Germ Cell and Embryonal. ... Breast Neoplasms. Receptor, ErbB-2. Disease-Free Survival. Tamoxifen. ...
mammary neoplasms (animal) Agriculture & Biology 100% * viral proteins Agriculture & Biology 86% * Viral Proteins Medicine & ... title = "Synthesis of murine mammary tumor viral proteins in vitro",. abstract = "The coding potential of murine mammary tumor ... Synthesis of murine mammary tumor viral proteins in vitro. / Sen, G. C.; Racevskis, J.; Sarkar, N. H. In: Journal of virology, ... Sen, G. C. ; Racevskis, J. ; Sarkar, N. H. / Synthesis of murine mammary tumor viral proteins in vitro. In: Journal of virology ...
... treatment of females of a mammary-tumour-virus-bearing strain.. Three distinctive types of neoplasm were induced in hamsters by ... 5.1 Animal carcinogenicity data. Testosterone was tested by subcutaneous injection and/or implantation in mice, rats and ... The only study in rats was considered inadequate in numbers of animals.. The incidences of leukaemia and of liver-cell and ... breast tumours in untreated mice of some strains were decreased by testosterone treatment, but the incidence of mammary tumours ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary Neoplasms. Mammary Neoplasms, Animal. C06 - DIGESTIVE SYSTEM DISEASES. Bile Duct Obstruction, Extrahepatic. Cholestasis ... C04 - NEOPLASMS. Carcinoma, Infiltrating Duct. Carcinoma, Ductal, Breast. ...
Mammary neoplasms are described as the third most common type of feline tumor, after haematopoietic and skin tumors, and ... prognosis and treatment of feline mammary tumors. Brazilian Journal of Veterinary Research and Animal Science, 55(2), e135084. ... Consensus for the diagnosis, prognosis and treatment of feline mammary tumors Authors. * Geovanni Dantas Cassali Universidade ... The main aspects of the diagnosis, prognosis and treatment of feline mammary neoplasia were discussed, aiming to standardize ...
An increase in mammary, pituitary and endocrine pancreas neoplasms has been found in rodents after chronic administration of ... 13.2 Animal Toxicology 14 CLINICAL STUDIES 14.1 Schizophrenia 14.2 Bipolar Mania - Monotherapy 14.3 Bipolar Mania - Adjunctive ... An increase in pituitary gland, mammary gland and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and ... 13.2 Animal Toxicology Juvenile dogs were treated for 40 weeks with oral risperidone doses of 0.31, 1.25, or 5 mg/kg/day. ...

No FAQ available that match "mammary neoplasms animal"